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Abstract
Background: Surgery can cure a significant percentage of ovarian carcinoma confined to the
pelvis. Nevertheless, there is still a 10–50% recurrence rate. We administered paclitaxel/
carboplatin as adjuvant treatment in early-stage ovarian carcinoma.
Methods: Patients with stages Ia or Ib, Grade 2 or 3 and Ic to IIb (any grade) were included.
Patients were treated with 4 cycles of Paclitaxel 175 mg/m2 and Carboplatin [area under the curve
(AUC) 6 (Calvert Formula)] every 3 weeks.
Results: Sixty-nine patients with no residual disease following cytoreductive surgery and minimal
or modified surgical staging were included in this analysis. Grade 3 or 4 neutropenia occured in
29.9% of patients, while neutropenic fever was reported in 4.5%. Neurotoxicity (all Grade 1 or 2)
was reported in 50% of cases. Median follow-up was 62 months. 5-year overall survival (OS) and
relapse-free survival (RFS) were: 87% (95% confidence intervals [CI]: 78–96) and 79% (95% CI: 69–
89), respectively. Significantly fewer patients with stages Ic-IIb and tumor grade 2 or 3 achieved a
5-year RFS than patients with only one of these two factors (73% vs 92%, p = 0.03).
Conclusion: Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in
early-stage ovarian carcinoma. Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from
more extensive treatment.
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Background
Ovarian cancer is a common malignancy. In most cases
the disease is diagnosed at an advanced stage. Neverthe-
less, about 30% of patients present with early-stage dis-
ease, i.e. confined to the pelvis without spread outside the
gynaecological organs (FIGO stages I and II). Surgery
alone can cure a significant percentage of these patients.
Nevertheless, there is a 10–50% recurrence rate, depend-
ing on stage, differentiation and histological type [1-3].
Therefore, research has been focused in developing adju-
vant treatment for patients in high-risk of relapse. Histor-
ically, radiotherapy, either as external beam
abdominopelvic irradiation or as intraperitoneal (i.p.)
32P, was the first modality to be tested in early ovarian
cancer. Although radiotherapy is effective in ovarian can-
cer, its use in this setting was not supported by the results
of phase II and III studies [1,4-6], while its toxicity, espe-
cially of 32P, is substantial and cisplatin monotherapy was
shown to be more effective and less toxic than 32P in one
randomized study [5]. Therefore, systemic chemotherapy
represents the adjuvant treatment, which has been tested
in the most recent studies.
Few randomized trials have addressed the question
whether adjuvant chemotherapy is of benefit in early
ovarian cancer [5-10]. In the first three studies no survival
benefit was shown [5-7], although in one study cisplatin
produced a significant improvement in disease-free sur-
vival [6]. However, all these trials lacked statistical power
to detect realistic but clinically relevant differences.
Recently, two large randomized trials and a joint analysis
of the results of the two trials (including 925 patients)
have been published [8-10]. Treatment was not uniform
since various combinations as well as single-agent plati-
num-based chemotherapy were acceptable, while the
requirements of surgical staging, a factor, which is critical
for prognosis but also for the interpretation of the results
[4,6,8] were also different. In spite of these methodologi-
cal differences, both trials showed a significant improve-
ment of recurrence-free survival, while one of them as well
as the joint analysis also showed a significant prolonga-
tion of 5-year survival by 8–9% [9,10].
In all previous studies most patients received cisplatin or
carboplatin monotherapy or cisplatin-based combination
chemotherapy without paclitaxel. The latter agent has
recently emerged as an integral component of the stand-
ard first-line treatment for advanced ovarian cancer in
combination with cisplatin or carboplatin, after the
results of three randomized studies [11-13]. Nevertheless,
its role in early stage disease had not until recently been
studied.
Since 1996 most centers of the Hellenic Cooperative
Group have been treating patients with stages I-IIb epithe-
lial ovarian cancer with the combination carboplatin and
paclitaxel after surgery. We are now reporting a retrospec-
tive analysis of the toxicity and efficacy of this combina-
tion in patients with a minimum follow up of 2 years.
Methods
Patients
All patients included in this analysis were managed in 4
centers of the Hellenic Cooperative Oncology Group
(HECOG). This retrospective analysis was approved by
the Scientific Committee of HECOG. The selection of
patients was based on the following uniform criteria
regarding the quality of surgery, administration of chem-
otherapy and follow up protocols. All patients had stages
Ia or Ib, Grade II or III or any Grade Ic-IIb epithelial ovar-
ian cancer. Patients with sex cord, germ cell or borderline
tumors were not included. All patients had uniform surgi-
cal treatment and staging, which included at least: total
abdominal hysterectomy (TAH) with bilateral salpin-
goophorectomy (BSO), inspection and palpation of all
peritoneal surfaces and retroperitoneal area, biopsies of
suspect lesions for metastases, infracolic omentectomy
and peritoneal washings. Patients with other malignan-
cies or WHO performance status > 2 were not included.
All patients had normal bone marrow and liver function,
serum creatinine ≤ 2 g/dl, no uncontrolled cardiac
arrhythmias, heart or respiratory failure and negative
post-surgery CT scan of the abdomen and pelvis. All sur-
viving patients included in the analysis had a minimum
follow-up of 2 years.
Chemotherapy
Chemotherapy was initiated within 2 months from sur-
gery apart from one case, where chemotherapy was started
4 months after surgery due to postsurgical complications.
Paclitaxel at 175 mg/m2 over 3 hours immediately fol-
lowed by Carboplatin over 60 minutes were administered
every 3 weeks. Four cycles of chemotherapy were admin-
istered. Carboplatin dose was based on the Calvert For-
mula to predict an AUC of 6 [14,15]. Chemotherapy was
administered on schedule if neutrophil count was ≥ 1.5 ×
109/L (normal range: 2–7.5) and the platelet count ≥ 100
× 109/L (normal range: 140–450). If absolute neutrophil
count (ANC) was < 1.5 × 109/L Granulocyte-colony stim-
ulating factor (G-CSF) was administered until ANC recov-
ery. If only one week delay was required, next
chemotherapeutic courses were given every 4 weeks.
Apart from the addition of G-CSF no other dose modifica-
tions were applied for neutropenia with the exception of
prolonged (more than 7 days with ANC < 0.5 × 109/L)
neutropenia, or febrile neutropenia in G-CSF supported
patients. In these cases a 25% doses reduction for both
drugs was performed. The following dose modifications
were applied according to the nadir value of platelets: ifBMC Cancer 2006, 6:228 http://www.biomedcentral.com/1471-2407/6/228
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platelets were between 25–49 × 109/L a 25% dose reduc-
tion (all drugs) was made, while a 50% dose reduction
was applied for platelet counts below 25 × 109/L.
Follow-up
Tumor assessment with chest X-ray, CTscan of the abdo-
men and pelvis and CA 125 was performed after comple-
tion of chemotherapy. Patients were then followed up
every 3 months for the first two years, 6-monthly for the
following 3 years and subsequently every year with phys-
ical examination (including gynaecological), CT scan of
the abdomen and pelvis, chest X-ray and CA 125. Addi-
tional investigations were performed if clinically indi-
cated.
Statistical considerations
Overall survival (OS) and relapse-free survival (RFS) were
calculated from the day of initiation of treatment until the
date of last follow-up, death (for OS) or relapse (for RFS).
Only radiological or clinical evidence of disease was con-
sidered as relapse, while the sole CA125 elevation above
the upper normal limit was not. Survival curves were pro-
duced with the Kaplan Meier method and survival func-
tions were compared across different groups with the log-
rank test [16]. Missing values in any of the studied varia-
bles were omitted from the analyses. All analyses were
performed using the SPSS statistical software (SPSS for
Windows, version 10, SPSS Inc., Chicago, IL). Throughout
the analysis a level of 5% was used to denote statistical sig-
nificance except as indicated.
Results
Patients
Sixty-nine consecutive patients with stage I-IIb epithelial
ovarian cancer, treated with chemotherapy between May
1996 and September 2002, who fulfilled the criteria men-
tioned above, have been included in this analysis. Base-
line characteristics are shown in Table 1. All patients
underwent optimal surgical debulking (i.e. no residual
disease after cytoreductive surgery). Oophorectomy was
performed in two patients who had undergone hysterec-
tomy in the past. Fertility-preserving surgery (unilateral
oophorectomy + omentectomy) was performed in one
patient who had a successful pregnancy following the
completion of chemotherapy. The predominant histolog-
ical types were serous (29%) and endometrioid adenocar-
cinomas (26.1%), while "other" carcinomas included a
malignant Brenner tumor, a transitional cell carcinoma
and a mixed (mucinous + endometrioid) adenocarci-
noma. Baseline CA125 level was missing in 10 patients.
Twenty of the 59 patients (34%) with available baseline
CA125 had elevated levels (> 37 U/ml). The median pre-
treatment CA125 in patients with elevated values was 66.5
U/ml (range 37–224). In 19 cases CA125 value normal-
ized during treatment. In the remaining case the patient
refused to provide further CA125 evaluation.
Chemotherapy
Four cycles of Paclitaxel/Carboplatin were administered
in all but 4 cases: 1 cycle of chemotherapy was adminis-
tered in 2 cases (one patient developed renal failure after
the first cycle of chemotherapy and the other refused fur-
ther treatment), 3 cycles in 1 case (the patient developed
pulmonary edema not related to chemotherapy after the
third cycle and did not receive the fourth cycle) and pacl-
itaxel was omitted from the 3 final cycles in one case of
anaphylaxis after the first administration of paclitaxel.
Toxicity data were not available in 2 cases. Alopecia was
universal. The remaining toxicities are shown in Table 2.
There were 20 cases (29.9%) of grade 3/4 neutropenia,
Table 1: Patients characteristics at the initiation of 
chemotherapy
Characteristic Pts (%)
Age
Median (range) 57 (24–78)
Stage
Ia 15 (21.8)
Ib 1 (1.4)
Ic 47 (68.2)
IIa 5 (7.2)
IIb 1 (1.4)
Histology
Serous 20 (29)
Endometrioid 18 (26.1)
Mucinous 10 (14.5)
Clear cell 11 (15.9)
Poorly differentiated 5 (7.2)
Adenocarcinoma (not specified) 2 (2.9)
Other 3 (4.4)
Grade (n = 66)
1 12 (18.2)
2 36 (54.5)
3 18 (27.3)
Missing 3
Type of surgery
TAH+BSO 7 (10.1)
TAH+BSO+omentectomy 51 (74)
TAH+BSO+omentectomy+LND 8 (11.6)
BSO+omentectomy 2 (2.9)
BSO 1 (1.4)
Baseline CA125 (n = 59)
Elevated 20 (34)
Normal 39 (66)
TAH: total abdominal hysterectomy; BSO: bilateral 
salpingoophorectomy; LND: lymphadenectomyBMC Cancer 2006, 6:228 http://www.biomedcentral.com/1471-2407/6/228
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which was complicated with fever in only 3 cases (4.5%).
Non hematological Grade 3 or 4 toxicities were reported
in only 4 cases: 1 renal, 1 vomiting, 1 liver and 1 allergy.
The most frequent non-hematological toxicity was neuro-
toxicity, which was reported in 33 patients (49.3%). Aller-
gic reaction was reported in 1 case with anaphylaxis
(1.5%). There were no treatment related deaths.
Relapse-free and overall survival
Median follow-up at the time of analysis was 62 months
(22–97.5). During follow-up 14 patients relapsed and 7
died due to progression of their disease. All but two
relapses occurred in patients with stages Ic and II and
tumors of grade 2 or 3. Intraabdominal disease was the
site of relapse in all but two cases who also had supradia-
phragmatic disease. All but one relapses occurred within 5
years from the initiation of chemotherapy.
Five-year RFS of the whole population was 79% (95% CI:
69–89) (figure 1) and 5-year OS was 87% (95% CI: 78–
96) (figure 2). Table 3 shows the respective values accord-
ing to grade and stage. RFS or OS were worse for patients
with stages Ic and II and for patients with tumor grade 2
or 3 but these differences were not statistically significant.
In addition, there were no significant differences among
different histological types (p = 0.32) or according to
baseline CA125 (normal vs. abnormal, p = 0.97). When
stage and grade were combined, patients with stages Ic
and II AND grade 2 or 3 had a significantly worse RFS
compared to the remaining patients (5-year RFS 73% vs.
92%, p = 0.03) (Figure 3), while OS survival was also
worse but this difference was not statistically significant
(5-year OS 84% vs. 93%, p = 0.58) (Figure 4).
Discussion
The role of systemic chemotherapy in ovarian cancer con-
fined to the pelvis (FIGO stages I and II) remains contro-
versial. Data from recent randomized studies [8-10] and
systemic reviews of adjuvant treatments used in these
patients [17] suggest that there is a benefit from platinum-
based chemotherapy. Nevertheless, several important
issues, i.e. the role of taxanes, the number of cycles and
the selection of patients most likely to benefit from this
treatment, remain unanswered.
We used 4 cycles of carboplatin/paclitaxel as adjuvant
treatment in optimally debulked patients with I-IIb ovar-
ian carcinoma. We did not include patients with stages Ia,
Ib and Grade 1, since they have an excellent prognosis
without adjuvant therapy [4,17]. There are no published
data on the efficacy and tolerability of this regimen in this
setting, since it has only recently been accepted as the
Relapse-free survival of 69 patients treated with paclitaxel/ carboplatin for  early-stage (FIGO stages I-IIb) ovarian carci- noma Figure 1
Relapse-free survival of 69 patients treated with paclitaxel/
carboplatin for  early-stage (FIGO stages I-IIb) ovarian carci-
noma.
Table 2: Worst toxicity of 67 patients who received Paclitaxel/Carboplatin
Toxicity 0 n(%) 1 n(%) 2 n(%) 3 n(%) 4 n(%)
Anemia 31 (46.3) 29 (43.3) 7 (10.4) 0 (0) 0 (0)
Neutropenia 21 (31.3) 6 (9) 20 (29.8) 14 (20.9) 6 (9)
Thrombocytopenia 64 (95.5) 2 (3) 1 (1.5) 0 (0) 0 (0)
N+V 45 (67.2) 18 (26.8) 3 (4.5) 1 (1.5) 0 (0)
Renal 66 (98.5) 0 (0) 0 (0) 0 (0) 1(1.5)
Diarrhea 66 (98.5) 1 (1.5) 0 (0) 0 (0) 0(0)
Stomatitis 65 (97) 0 (0) 2 (3) 0 (0) 0 (0)
Neurotoxicity 34 (50.7) 27 (40.3) 6 (9) 0 (0) 0 (0)
Liver 66 (98.5) 0 (0) 0 (0) 1 (1.5) 0 (0)
Allergy 66 (98.5) 0 (0) 0 (0) 0 (0) 1 (1.5)
Neutropenic fever 64 (95.5) N/A N/A 3 (4.5) 0 (0)BMC Cancer 2006, 6:228 http://www.biomedcentral.com/1471-2407/6/228
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standard in more advanced ovarian cancer [11,12]. By vir-
tue of the Goldie hypothesis, this regimen should work
better in earlier stages. For this reason we believe that the
information reported here is of interest, since it is likely
that this combination will also be extensively studied in
early-stage ovarian cancer. This speculation is supported
by the fact that this regimen has been used in a recent ran-
domized trial [18]. The number of cycles was chosen
because of our previous experience, which showed excel-
lent toxicity profile in patients with bladder cancer [19].
Additionally, there were no data regarding the optimal
number of cycles in early ovarian cancer at the time of the
initiation of this treatment. In concert with our previous
experience treatment was well tolerated. Grade 3 and 4
toxicities were rare except from neutropenia, which, how-
ever, had no clinical sequelae in all but 3 cases. Neurotox-
icity was also frequent (50% of cases) but no grade 3 or 4
toxicities were reported.
The 5-year RFS of 79% and OS of 87% in our study are
comparable to those reported by others for stages I and II
disease receiving adjuvant platinum-based chemotherapy
(Table 4). Baseline tumor stage, grade and histology of
our patients are similar to those included in other studies.
Although the retrospective nature of our study is a limita-
tion in the interpretation of our findings and direct com-
parisons can only be validated through randomized trials,
our results indicate that 4 cycles of carboplatin/paclitaxel
is not an inferior treatment compared to previously used
combinations or monotherapy (Table 4).
In spite of the apparent efficacy of our regimen, the fol-
lowing factors should be taken into consideration for the
interpretation of our results: surgical staging, type of
chemotherapy and number of administered cycles of
chemotherapy. The importance of surgical staging in the
prognosis and management of early-stage ovarian cancer
has long been recognized [6,21,22]. This was also shown
in the recent EORTC trial where 4 different categories of
surgical staging (optimal, modified, minimal and inade-
quate) were clearly defined [8]. Although the quality of
surgical staging was not predefined according to this sys-
tem, the selection of our patients required at least mini-
mal surgical staging (TAH and BSO, inspection and
palpation of all peritoneal surfaces and the retroperito-
neal area, biopsies of all suspect lesions, peritoneal wash-
Table 3: Five-year overall survival and relapse-free survival of 69 patients who received Paclitaxel/Carboplatin
5y OS (95% CI) P* 5y RFS (95% CI) P*
All patients (n = 69) 87% (78–96) no of deaths: 7 79% (69–89) no of relapses: 14
Stage .81 .28
Ia, Ib (n = 16) 94% (82–100) No of deaths: 1 93% (79–100) No of relapses: 1
Ic, II (n = 53) 86% (75–97) No of deaths: 6 78% (66–90) No of relapses: 13
Grade .88 .30
1 (n = 12) 92% (76–100) No of deaths: 1 92% (76–100) No of relapses: 1
2,3 (n = 54) 86% (75–97) No of deaths: 6 78% (66–90) No of relapses: 13
Ia/Ib OR grade 1 (n = 28) 93% (83–100) No of deaths: 2 .58 92% (82–100) No of relapses: 2 .03
Ic/II AND grade2/3 (n = 39) 84% (71–97) No of deaths: 5 73%(58–88) No of relapses: 12
*p values estimated with log rank test
Overall survival of 69 patients treated with paclitaxel/carbo- platin for early-stage (FIGO stages I-IIb) ovarian carcinoma Figure 2
Overall survival of 69 patients treated with paclitaxel/carbo-
platin for early-stage (FIGO stages I-IIb) ovarian carcinoma.BMC Cancer 2006, 6:228 http://www.biomedcentral.com/1471-2407/6/228
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ings and omentectomy). Information about the quality of
surgery was based on the operative notes, which were
available in 60 of the 69 cases. In the remaining 9 cases
details of surgery was obtained by the treating physician.
In 61 cases surgical staging was minimal while in the 8
cases of lymph node sampling it could be categorized as
modified. Therefore, inaccurate staging cannot be
excluded in some cases since about 17% of presumed
stage I inadequately staged patients are upstaged to stage
III after proper surgical staging [23]. Nevertheless, this
type of surgery reflects the surgery performed in most ran-
domized trials studying adjuvant treatment in early stage
ovarian cancer [17], while suboptimal surgical staging is a
well recognized problem in early ovarian cancer [24,25].
Even in the EORTC trial most patients underwent modi-
fied or minimal surgical staging [8]. In the same study
there was no prognostic significance of surgical staging
among patients who received chemotherapy. For the
above reasons we believe that our results are clinically rel-
evant.
The use of paclitaxel/platinum combination as opposed
to the less neurotoxic platinum monotherapy in early
ovarian cancer remains an unresolved issue. Monotherapy
or treatment with cisplatin/cyclophosphamide have been
mainly used in most studies up to now [1,5,8,9,20]. The
combination of paclitaxel with cisplatin or carboplatin
has been proposed as the standard in advanced disease
Table 4: Published studies of adjuvant chemotherapy in early stage ovarian cancer
Study Type of study Treatment Pts 5y RFS 5y OS
Young, 19906 Prospective, randomized Melphalan 32P 68 73 80% 80% 81% 78%
Vergote, 19921 Prospective, randomized Cisplatin 32P 171 169 81% 83% 75% 81%
Bolis, 19955 Prospective, randomized Cisplatin 32P 82 79 85% 65% 81% 79%
Young, 199920 Prospective, randomized Cyclo/Cisplatin 32P 107 98 77% 66% 84% 76%
Trope, 20007 Prospective, randomized Carboplatin No treatment 81 81 70% 71% 86% 85%
Trimbos, 20038 Prospective, randomized Platinum-based No treatment 224 224 76%* 68% 85% 78%
ICON1, 20039 Prospective, randomized Platinum-based No treatment 241 236 73%@ 62% 79%# 70%
Present study Retrospective, nonrandomized Paclitaxel/Carboplatin 69 79% 87%
RFS: relapse-free survival; OS: overall survival; *: p = 0.02; @: p = 0.01; #: p = 0.03
Relapse-free survival of patients with stages Ia/Ib OR tumor  grade 1 (--)  vs. stages Ic/IIa/IIb AND tumor grade 2/3 (-) Figure 3
Relapse-free survival of patients with stages Ia/Ib OR tumor 
grade 1 (--)  vs. stages Ic/IIa/IIb AND tumor grade 2/3 (-).
Overall survival of patients with stages Ia/Ib OR tumor grade  1 (--) vs. stages Ic/IIa/IIb AND tumor grade 2/3 (-) Figure 4
Overall survival of patients with stages Ia/Ib OR tumor grade 
1 (--) vs. stages Ic/IIa/IIb AND tumor grade 2/3 (-).BMC Cancer 2006, 6:228 http://www.biomedcentral.com/1471-2407/6/228
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but a recent randomized study showed no survival advan-
tage over carboplatin monotherapy [26]. Therefore, it is
important to determine any possible advantage of paclit-
axel/platinum combination compared to platinum mon-
otherapy taking into consideration the high percentages
of alopecia and neurotoxicity associated. In contrast, the
lower number of cycles of paclitaxel/carboplatin may be
more preferable to the patients than the 6 cycles usually
administered in the other studies. Since early stage ovar-
ian cancer represents a prognostically diverse population,
future studies should be focused on identifying the opti-
mal treatment for the various subgroups of patients. Until
then the standard chemotherapy in early stage remains
debatable, although it should be stressed that paclitaxel/
carboplatin has been used as the reference regimen in the
two more recent randomized studies in early stage ovarian
cancer [18,19].
The optimal number of cycles of chemotherapy in early-
stage ovarian cancer has not been adequately addressed.
Six cycles have been used in most studies [1,5,8,9]. This
issue has been addressed in a randomized trial, reported
in abstract form. Three cycles of paclitaxel/carboplatin
were compared with 6 cycles of the same treatment [18].
This study showed no significant difference in 5-year RFS
(73% vs. 81%), between the two arms. Anemia, granulo-
cytopenia, and neurotoxicity were significantly higher
with 6 cycles of treatment. These results indicate that 6
cycles of chemotherapy are not necessary for early ovarian
cancer. This speculation is also supported by our results,
since 4 cycles of chemotherapy achieved a 5-year RFS of
79%, similar to that reported after 6 cycles of treatment in
the study by Young et al. Nevertheless, it cannot be
excluded that some patients might benefit from more
chemotherapy. We attempted to address this issue by
identifying subgroups with inferior prognosis. Patients
with early-stage ovarian cancer represent a heterogeneous
group regarding their prognosis [2-4]. FIGO stage and
tumor grade are the most consistent prognostic factors
identified in previous studies [2-4,8]. We did not find any
prognostic significance of these or any other baseline
characteristic in our study. This could be due to the rela-
tively small number of patients included in this analysis.
Nevertheless, it should be stressed that tumor stage was
not associated with prognosis in a recent randomized trial
[8] as well as a metaanalysis of 1500 cases of stage I ovar-
ian cancer [27]. The combination of tumor stage and
grade identified a subgroup (stages Ic or II AND grade 2 or
3), which had a significantly inferior 5-year RFS compared
with patients with only one of these factors (73% vs.
92%). Although the number of our patients is relatively
small for subgroup analysis, we believe that these patients
may represent a target population, who might benefit
from the administration of 6 cycles of chemotherapy.
Conclusion
Four cycles of paclitaxel/carboplatin chemotherapy repre-
sent an effective and well tolerated adjuvant treatment in
this cohort of patients with stages I-IIb epithelial ovarian
carcinoma, who underwent minimal or modified surgical
staging. Patients with stages Ic/II and tumor grade 2/3 had
worse progression-free survival than patients with only
one of these factors and might benefit from the adminis-
tration of more cycles of chemotherapy.
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